Earnings Call · Q2 FY2023·2023-08-02

Q2 23EPS +5.66%·Rev n/aQ1 23EPS -27.27%·Rev n/aQ4 22EPS 0.00%·Rev n/aQ3 22EPS -4.84%·Rev n/a⚠ consensus missing

TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA

Ran Meir — Head of Investor Relations

Richard Francis — Chief Executive Officer

Dr. Eric Hughes — Medical Affairs or Clinical Development Executive

Eli Kalif — Chief Financial Officer

+11.6%1d on move date+13.0% vs SPY3d+17.7%5d+18.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TEVA calls or request research access.

More TEVA calls Browse calls Request research access